Cargando…
Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan
Immune checkpoint inhibitors (ICIs) are the standard treatment for non-small-cell lung cancer (NSCLC). We assessed the clinical prognostic factors in NSCLC patients receiving atezolizumab as a second- or later-line (2L+) treatment. Data were retrospectively collected for NSCLC patients treated with...
Autores principales: | Wu, Shang-Gin, Chiang, Chi-Lu, Wang, Chin-Chou, Hung, Jen-Yu, Hsia, Te-Chun, Kuo, Chih-Hsi, Shih, Jin-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330461/ https://www.ncbi.nlm.nih.gov/pubmed/35912016 http://dx.doi.org/10.7150/jca.74617 |
Ejemplares similares
-
An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2020) -
Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting
por: Chang, Hui-Min, et al.
Publicado: (2022) -
When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan
por: Chen, Chieh-Lung, et al.
Publicado: (2022) -
The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan
por: Cheng, Wen‐Chien, et al.
Publicado: (2022) -
Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
por: Alonso-García, Miriam, et al.
Publicado: (2022)